Corona Remedies Ltd
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.[1]
- Market Cap ₹ 12,878 Cr.
- Current Price ₹ 2,106
- High / Low ₹ 2,210 / 1,337
- Stock P/E 60.7
- Book Value ₹ 122
- Dividend Yield 0.47 %
- ROCE 33.3 %
- ROE 29.5 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.5%
- Company has been maintaining a healthy dividend payout of 29.3%
Cons
- Stock is trading at 17.2 times its book value
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| 884 | 1,014 | 1,196 | 1,403 | 1,479 | |
| 756 | 859 | 956 | 1,109 | 1,162 | |
| Operating Profit | 128 | 156 | 241 | 294 | 317 |
| OPM % | 14% | 15% | 20% | 21% | 21% |
| 7 | 5 | 6 | -9 | -7 | |
| Interest | 4 | 14 | 11 | 7 | 8 |
| Depreciation | 20 | 28 | 37 | 38 | 42 |
| Profit before tax | 111 | 118 | 199 | 240 | 260 |
| Tax % | 23% | 24% | 25% | 23% | |
| 85 | 90 | 149 | 185 | 199 | |
| EPS in Rs | 13.89 | 14.80 | 24.43 | 30.27 | 32.54 |
| Dividend Payout % | 20% | 25% | 30% | 33% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 17% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 27% |
| Last Year: | 30% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 61 | 61 | 61 | 61 |
| Reserves | 347 | 419 | 545 | 686 |
| 28 | 159 | 86 | 165 | |
| 159 | 191 | 237 | 293 | |
| Total Liabilities | 595 | 831 | 930 | 1,205 |
| 185 | 384 | 370 | 554 | |
| CWIP | 65 | 121 | 186 | 143 |
| Investments | 32 | 26 | 26 | 26 |
| 314 | 301 | 348 | 482 | |
| Total Assets | 595 | 831 | 930 | 1,205 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 103 | 157 | 190 | 229 | |
| -50 | -267 | -84 | -256 | |
| -45 | 99 | -107 | 25 | |
| Net Cash Flow | 8 | -11 | 0 | -1 |
| Free Cash Flow | 9 | -129 | 99 | 56 |
| CFO/OP | 100% | 112% | 97% | 95% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 36 | 36 | 36 | 38 |
| Inventory Days | 182 | 158 | 200 | 175 |
| Days Payable | 163 | 184 | 221 | 206 |
| Cash Conversion Cycle | 55 | 10 | 14 | 7 |
| Working Capital Days | 30 | -2 | 9 | -15 |
| ROCE % | 25% | 32% | 33% |
Insights
In beta| Mar 2020 | Mar 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Medical Representative (MR) Strength count |
|
|||||
| Chronic & Sub-chronic Share of Revenue % of domestic sales |
||||||
| IPM Market Rank rank |
||||||
| IPM Market Share % |
||||||
| Number of Engine Brands count |
||||||
| Per Capita Per Month (PCPM) Productivity INR lakhs per MR per month |
||||||
| Pharmacies Covered count |
||||||
| Unique Doctors Covered count |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11h - Q1 FY27 earnings conference call audio recording available on company website.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Newspaper Publication of Unaudited Financial Results for the first quarter and three months ended June 30, 2026
- Announcement under Regulation 30 (LODR)-Investor Presentation 31 Jul
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
31 Jul - Q1FY27 revenue rose 21.9% to ₹422.4 Cr; PAT up 30.1%; female hormone plant commercialized.
- Unaudited Financial Results For The First Quarter And Three Months Ended June 30, 2026 31 Jul
Concalls
-
Aug 2026TranscriptPPT REC
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT
-
Jan 2026Transcript PPT REC
Market Leadership[1]
The Company holds strong positions across key therapies, ranking #5 in Women’s Healthcare, #5 in Pain Management, #9 in Urology, and #20 in Cardio-Diabeto. It is also ranked #14 in the overall Indian Pharmaceutical Market (IPM), with notable rankings of #6 in Orthopaedics, #7 in Gynaecology, #11 in Consulting Physicians and Diabetology, and #14 in Cardiology and Urology.